Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 13/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197920 | 1.00 | PYGL (0.53) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL2936321 | 1.00 | PYGL (0.53) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL12035319 | 0.89 | PYGL (0.55) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL4083417 | 0.88 | PYGL (0.54) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL10476621 | 0.88 | PYGL (0.54) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL12631299 | 0.88 | PYGL (0.54) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL4083424 | 0.88 | PYGL (0.54) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL4093196 | 0.88 | PYGL (0.54) | PYGLSMYD3EHMT2EGFRNHERF1 | |
| SCHEMBL12101101 | 0.83 | SMYD3 (0.59) | PYGLSMYD3EHMT2NHERF1F10 | |
| SCHEMBL1859655 | 0.82 | PYGL (0.52) | PYGLSMYD3EHMT2EGFRNHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1270557-B1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | PYGL 1260/4885SMYD3 4107/4885EHMT2 4292/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | PYGL 3056/4885SMYD3 995/4885EHMT2 833/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | PYGL 4129/4885SMYD3 3410/4885EHMT2 4646/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | PYGL 3803/4885SMYD3 3513/4885EHMT2 4507/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | PYGL 3803/4885SMYD3 3513/4885EHMT2 4507/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | PYGL 1509/4885SMYD3 2701/4885EHMT2 2085/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | PYGL 3866/4885SMYD3 3337/4885EHMT2 4458/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | PYGL 2722/4885SMYD3 1262/4885EHMT2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.